Gliomas are incurable brain tumors. Researchers are trying to unlock the mysteries of how they originate from normal cells, which may lead to better treatments.
New first in the world Zap-X Gyroscopic radiosurgery equipment paired with brain only Synaptive MRI for treatment of brain tumors and other conditions
Glioblastoma cells are poised near a “critical point” of order and disorder — meaning, the cells possess some form of large-scale coordination throughout the whole tumor that allows them to respond in practical unison to attempts to kill tumor cells, such as chemotherapy or radiation, a study suggests. Researchers say disrupting the large-scale organization of brain tumors may result in more powerful ways to treat and one day eliminate brain tumors.
A new international study published in and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma. Drs. Farshad Nassiri and Gelareh Zadeh, neurosurgeons and scientists at the University Health Network (UHN) in Toronto, published the results of a Phase 1/2 clinical trial investigating the safety and effectiveness of a novel therapy which combines the injection of an oncolytic virus – a virus that targets and kills cancer cells – directly into the tumour, with intravenous immunotherapy.
Malignant gliomas are deadly brain tumors with no cure. We engineered herpes simplex virus (HSV)-1 and developed oncolytic HSV (oHSV) to treat brain tumors, given its potential to selectively kill tumor cells while sparing normal brain cells, and to boost…
Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
Researchers at the University of Waterloo have created a computational model to predict the growth of deadly brain tumours more accurately.
Dramatic results in glioblastoma research: eliminating the astrocytes (a major class of brain cells) surrounding the tumors or inhibiting their ability to supply energy to the glioblastoma cells resulted in cancer cell death, and tumor regression within several days.
Newly-published NCCN Guidelines for Pediatric Central Nervous System Cancers synthesize latest evidence to help care teams ensure children with high-grade gliomas have best possible outcomes; available free at NCCN.org.
UT Southwestern is joining with medical centers around the nation to apply advanced sequencing to pediatric brain tumors as part of the National Cancer Institute’s new Molecular Characterization Initiative, a subset of the Cancer Moonshot Childhood Cancer Initiative.
The Center for Data Driven Discovery at CHOP will procure molecular characterization for thousands of these brain tumor samples providing an unprecedented level of insight into devastating cancers and paving the way for future therapeutic interventions.
Hopkins Med News Update
Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.
To better understand brain cancer, neuro-oncologist Michael E. Salacz, MD, director of the Neuro-Oncology Program at Rutgers Cancer Institute of New Jersey and associate professor of medicine at Rutgers Robert Wood Johnson Medical School, shares some basic information on types of brain tumors, risk factors and treatment options.
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
Yale School of Medicine announces a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Chênevert Family Brain Tumor Center will be a leading center in Neuro-Oncology research worldwide, bringing ground-breaking solutions and hope to patients with brain tumors.
Story of a man who celebrated his five-year survival with GBM. He received 5-ALA prior to surgery, which helps the surgeon see more of the tumor for removal, and he was in a Phase 1 clinical trial.
Announcement of University Hospitals Cleveland Medical Center and UH Seidman Cancer Center obtaining the Medtronic Stealth Autoguide cranial robotic guidance platform for neurosurgery.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
In experiments with human cells and mice, researchers at the Johns Hopkins Kimmel Cancer Center report evidence that combining the experimental cancer medication TAK228 (also called sapanisertib) with an existing anti-cancer drug called trametinib may be more effective than either drug alone in decreasing the growth of pediatric low-grade gliomas. These cancers are the most common childhood brain cancer, accounting for up to one-third of all cases. Low grade pediatric gliomas arise in brain cells (glia) that support and nourish neurons, and current standard chemotherapies with decades-old drugs, while generally effective in lengthening life, often carry side effects or are not tolerated. Approximately 50% of children treated with traditional therapy have their tumors regrow, underscoring the need for better, targeted treatments.